Oligometastatic Disease Clinical Trials

24 recruiting

Oligometastatic Disease Trials at a Glance

24 actively recruiting trials for oligometastatic disease are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Mumbai, Surrey, and Beijing. Lead sponsors running oligometastatic disease studies include Fudan University, Tata Memorial Hospital, and University of Maryland, Baltimore.

Browse oligometastatic disease trials by phase

Treatments under study

About Oligometastatic Disease Clinical Trials

Looking for clinical trials for Oligometastatic Disease? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligometastatic Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligometastatic Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 2

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR30 enrolled14 locationsNCT06180356
Recruiting
Not Applicable

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of LifeOligometastatic DiseaseToxicity Due to Radiotherapy+1 more
Robert Olson598 enrolled13 locationsNCT05784428
Recruiting
Phase 1

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Oligometastatic DiseaseOligometastasis
Case Comprehensive Cancer Center15 enrolled1 locationNCT07079098
Recruiting
Early Phase 1

Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography

Oligometastatic Disease
Katelyn Atkins10 enrolled1 locationNCT06373497
Recruiting
Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Oligometastatic DiseaseOligoProgressive Metastatic DiseaseOligoprogression
British Columbia Cancer Agency194 enrolled1 locationNCT06918951
Recruiting
Not Applicable

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting
Phase 1Phase 2

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Solid Tumor, AdultOligometastatic Disease
Gustave Roussy, Cancer Campus, Grand Paris58 enrolled2 locationsNCT06439888
Recruiting
Phase 2

TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate CancerOligometastatic Disease
University of Maryland, Baltimore122 enrolled9 locationsNCT05223803
Recruiting
Phase 3

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

Oligometastatic DiseaseMetastatic Non Small Cell Lung Cancer
Tata Memorial Hospital190 enrolled1 locationNCT05278052
Recruiting
Phase 2

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

Non-small Cell Lung CancerOligometastatic DiseaseDriver Mutation
Tata Memorial Hospital106 enrolled1 locationNCT05277844
Recruiting
Not Applicable

Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions

Oligometastatic Disease
IRCCS San Raffaele307 enrolled1 locationNCT05679427
Recruiting
Not Applicable

Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)

Esophageal CancerGastric CancerOligometastatic Disease
University Health Network, Toronto72 enrolled1 locationNCT06668454
Recruiting
Phase 2

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Prostate CancerOligometastatic Disease
University of Maryland, Baltimore88 enrolled1 locationNCT06212583
Recruiting

Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare Tumors

Oligometastatic Disease
Istituto Clinico Humanitas200 enrolled1 locationNCT05903261
Recruiting
Not Applicable

Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs

Oligometastatic DiseaseUreter CancerRenal Pelvic Carcinoma
Peking University First Hospital102 enrolled2 locationsNCT06652022
Recruiting
Phase 2Phase 3

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

Oligometastatic Disease
National Medical Research Radiological Centre of the Ministry of Health of Russia100 enrolled1 locationNCT06556550
Recruiting
Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting
Phase 3

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Esophageal Squamous Cell CarcinomaOligometastatic DiseaseRadiotherapy
Fudan University354 enrolled1 locationNCT06190782
Recruiting
Phase 2

Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma

Oligometastatic Disease
Jiangxi Provincial Cancer Hospital63 enrolled3 locationsNCT05128201
Recruiting
Not Applicable

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

SurgeryOligometastatic DiseaseRadiotherapy+3 more
Gitte Fredberg Persson MD PhD1,200 enrolled11 locationsNCT06356779